Over the past five years, the cosmetic industry has met with several legislative changes. Within the new legislative package, including the new REACH and CLP, it is important to find a comfortable routine that will minimize costs while staying effective and compliant with all regulations.
The ugly truth about being beautiful
Cosmetic testing that uses animals is notably controversial. Dripping chemicals into the eyes, shaving the fur and deliberate irritation to skin, long exposure to potential carcinogens or dangerous substances without pain relief drugs…
Even if not tested, products often include substances like animal fat, fish scales, hormones, stomach enzymes, gelatin, liver oil, animal gland steroids, wax and honey or even shark and turtle oil.
The European Union took a step forward in March 2013, when a new law was fully implemented and made it illegal to sell animal-tested cosmetics in Europe, even if the testing was done outside Europe. However, vivisection (experimentation on live animals) continues. 1,170,326 signatures were collected, but the initiative to stop vivisection was denied by the EU Commission.
Despite the remarkable progress that’s been made, ingredients used in cosmetics may still be tested on animals in the EU under REACH, the world’s largest chemical testing programme. Also testing on animals for household products continues. And when you Google cosmetic companies that still test on animals, around 330 names come up!
Scientists should follow the three Rs in order to reduce the impact of research on animals: Reduction, Refinement and Replacement. Reducing the number of animals used in experiments and refining the experiment in a way that the animal suffers as little as possible should be commonplace when they can't abstain from the use of animals. But the third “R” is the best way to go – replacement with alternative methods such as in-vitro testing, research with human volunteers or test tube methods.
Products in Europe that are not tested on animals carry the symbol of the “Leaping Bunny”. Take action, look for information, sign petitions and check what products you are buying. #becrueltyfree
Interested in this topic?
Advanced Protein Aggregation & Characterization
This training will focus on occurrence of particles in drug products, effects of protein aggregates, critical process and parameters. Attendees will gain overview of on utility and limits of predictive experiments, learn concerns from the authorities and relevant aggregation guidelines, and more.
CMC Analytical Comparability: Methods & Strategies for Biologics, Biosimilars & Biobetters
Attendees will be introduced to comparability in biosimilar development, the analytical strategies of protein characterization of biosimilars, the structure of proteins, in vitro pharmacology and much more.
Corporate Compliance & Transparency in the Pharmaceutical Industry
This two-day conference will serve as a platform for an open and dynamic dialogue with HCPs and patients to achieve common goals. Learn how to embed compliance in the business and develop one simple system for managing compliance & transparency in a complex and regulated environment.
Driving the national agenda of Medical tourism through PX Excellence
Read the interview with Dr. Layla Al-Marzouqi, Director of Medical Tourism Council at Dubai Health Authority, and learn how to enrich patient experience and quality of healthcare.
No more trouble with dangerous good shipments
Global temperature controlled pharmaceutical shipments are constantly faced with new logistics challenges and regulations. This January 2017, IATA Dangerous Goods Regulations added further complexity to shipping cold chain products compliantly.
5 Changes in Signal Detection Management
The European Medicines Agency, regulatory authorities in the Member States and marketing authorisation holders are responsible for detecting and managing safety signals. A safety signal is generally defined as information about a new or known Adverse Event that may have been caused by a medicine, where it is therefore necessary to conduct further investigation. Evaluation of safety signals plays a major role within pharmacovigilance. Therefore, it is vital for regulatory authorities to know the latest updates detailing the risks and benefits of medicines. The EudraVigilance database is an important source of information on suspected adverse reactions and signals.